About three in five people diagnosed with uveal melanoma, the most common form of ocular melanoma, survive long-term, with five-year relative survival around 79% and a plateau near 60% at twenty years. But those averages conceal enormous variation. A small, genetically low-risk tumor caught early carries a prognosis close to the general population’s life expectancy, while a large tumor with certain chromosomal changes can carry a greater than 50% chance of metastasis within five years. Understanding where you fall on that spectrum depends on tumor size, location, cell type, and increasingly on genetic testing of the tumor itself.
What Ocular Melanoma Is and Who Gets It
Ocular melanoma arises from the pigment-producing cells (melanocytes) inside the eye. The vast majority originate in the uveal tract, which includes the choroid, ciliary body, and iris. Uveal melanoma accounts for the large majority of ocular melanoma cases, while conjunctival melanoma is far less common.1PubMed Central. Uveal melanoma: epidemiology, etiology, and treatment of primary disease Because the two behave quite differently, virtually all of the survival data discussed here pertains to uveal melanoma specifically.
Incidence varies strikingly by geography and ancestry. Northern and Western Europe and Oceania see the highest rates, generally eight or more cases per million people per year, while rates in Asia, Africa, and South America fall below two per million.2Investigative Ophthalmology & Visual Science. Worldwide Incidence of Ocular Melanoma and Correlation With Pigmentation-Related Risk Factors In the United States, incidence runs around five per million, and in Australia closer to eight per million.3Advances in Ophthalmology Practice and Research. Global incidence and prevalence in uveal melanoma The geographic pattern tracks closely with lighter eye color: a genetic variant strongly associated with blue irises correlates with higher ocular melanoma incidence across populations.2Investigative Ophthalmology & Visual Science. Worldwide Incidence of Ocular Melanoma and Correlation With Pigmentation-Related Risk Factors The median age at diagnosis is about 63, though the disease can appear at any age, including rarely in children and young adults.
Overall Survival Numbers
A large systematic review and meta-analysis estimated five-year relative survival at 79%, ten-year at 66%, and twenty-year at roughly 60%, where it plateaus through thirty years.4Communications Medicine. Long-term relative survival in uveal melanoma: a systematic review and meta-analysis “Relative survival” adjusts for expected deaths from other causes, so it isolates the excess mortality attributable to the cancer itself. A separate analysis of more than 10,000 cases in the SEER database over 42 years found closely matching numbers: relative survival plateaued around 60% from 20 to 30 years.5PLoS ONE. Uveal melanoma: Long-term survival
Those figures suggest that roughly two in five patients ultimately die of their disease. Importantly, the risk of dying from uveal melanoma falls steeply after the first decade. In the SEER analysis, the proportion of deaths attributable to the melanoma was about 1.3 times higher than expected in the first five years, then dropped rapidly after ten years, and metastatic death was rare beyond twenty years.5PLoS ONE. Uveal melanoma: Long-term survival Intriguingly, the meta-analysis found that patients who survive past twenty years may actually have a slight survival advantage over age- and sex-matched peers in the general population, possibly because long-term survivors represent a healthier-than-average subset who underwent years of close medical monitoring.4Communications Medicine. Long-term relative survival in uveal melanoma: a systematic review and meta-analysis
What Determines Individual Prognosis
The averages above flatten out a disease that is, in practice, two very different diseases depending on your tumor’s biology. Prognosis hinges on a handful of clinical and molecular factors.
On the clinical side, the features linked to worse outcomes include older age at diagnosis, larger tumor diameter and thickness, ciliary body involvement, tumor extension beyond the eye, and more advanced staging.6PubMed Central. Uveal melanoma: estimating prognosis The American Joint Committee on Cancer (AJCC) staging system captures much of this in its tumor size categories. In a study of over 7,700 patients, the chance of metastasis by five years ranged from 8% for the smallest tumors (T1) to 51% for the largest (T4). By twenty years, those numbers were 25% and 69%, respectively.7PubMed. American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients Tumor size alone, however, doesn’t tell the whole story. A small tumor with aggressive molecular features can be more dangerous than a larger tumor without them.
How Genetic Testing Changed the Picture
The single biggest shift in ocular melanoma prognostication over the past two decades has been the move toward molecular testing of the tumor itself, usually done on a tiny sample obtained by fine-needle biopsy at the time of treatment. Two complementary approaches have emerged: gene expression profiling (GEP) and chromosomal analysis.
A 15-gene expression profile test classifies tumors as either Class 1 (lower metastatic risk) or Class 2 (higher metastatic risk).8PubMed Central. The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma A large collaborative study recently showed that adding a second marker called PRAME further refines the picture. Five-year metastasis-free survival was about 96% for Class 1/PRAME-negative patients, 81% for Class 1/PRAME-positive, 58% for Class 2/PRAME-negative, and 45% for Class 2/PRAME-positive. In that analysis, the gene expression profile was the strongest independent predictor of metastasis, more powerful than AJCC stage, with PRAME status providing additional refinement.9PubMed Central. 15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)
When GEP class is layered on top of AJCC stage, the two systems together paint a very detailed picture. For example, among stage I tumors classified as Class 2 by gene expression, three-year metastasis-free survival was only 79%, while Class 1A patients at the same stage had a probability of 1.0 — no metastases at all at three years. For stage III tumors, Class 2 patients had just a 41% three-year metastasis-free survival, compared with 100% for Class 1A.10PubMed. Do Largest Basal Tumor Diameter and the American Joint Committee on Cancer’s Cancer Staging Influence Prognostication by Gene Expression Profiling in Choroidal Melanoma The upshot is clear: two tumors that look similar by size and stage can have wildly different trajectories depending on their molecular class.
Key Mutations and Chromosomal Changes
Behind the gene expression classes are specific mutations and chromosomal abnormalities. Three somatic mutations stand out. BAP1 mutations are associated with Class 2 gene expression profiles, older patient age, and high metastatic risk. By contrast, EIF1AX mutations associate with Class 1 profiles and the absence of ciliary body involvement, while SF3B1 mutations associate with younger age and a more favorable outlook.11JAMA Ophthalmology. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes
On the chromosomal side, loss of one copy of chromosome 3 (monosomy 3) is the best-known adverse marker. Tumors with monosomy 3 that also show epithelioid cell type and certain vascular patterns are predicted to have especially short survival.12PubMed. Artificial neural networks estimating survival probability after treatment of choroidal melanoma Gain of extra copies of chromosome 8q is another recurrent change, but its prognostic impact depends on context. In tumors carrying BAP1 mutations, 8q gain is correlated with decreased survival. In SF3B1-mutant tumors, however, 8q gain does not appear to add any additional prognostic information.13PubMed Central. 8q Gain Has No Additional Predictive Value in SF3B1 MUT Uveal Melanoma but Is Predictive for a Worse Prognosis in Patients with BAP1 MUT Uveal Melanoma
Why Metastasis Hits the Liver
Unlike skin melanoma, which tends to spread to many different organs, uveal melanoma is notoriously liver-tropic. Up to 90% of patients who develop metastatic disease have liver involvement, and many have liver-only disease. This isn’t random. Tumor cells that overexpress a receptor called c-Met enter the bloodstream through the tumor’s own vasculature. Circulating melanoma cells then home to the liver in response to a chemical signal gradient, lodge in the liver’s fine blood vessel network (the sinusoidal space), and trigger a local inflammatory cascade that helps them stick to the vessel walls and begin growing. Nearby stellate cells in the liver transform into support cells that build a scaffold for the growing metastasis, even before new blood vessels form.14JAMA Ophthalmology. Progression of Ocular Melanoma Metastasis to the Liver
Once liver metastases are established, the prognosis becomes very poor. Average survival after metastatic detection has historically been only a few months, though newer therapies are beginning to change that picture.
Treatment of the Primary Tumor
For the eye tumor itself, radiation therapy and surgical removal (enucleation) are the two main options. A landmark clinical trial, the Collaborative Ocular Melanoma Study (COMS), showed that survival after plaque radiation therapy and enucleation was comparable for medium-sized tumors, and radiation has since become the preferred approach for small and medium tumors because it can preserve the eye.15Journal of Medical Radiation Oncology. Radiation Therapy for Ocular Melanoma. Narrative Review with Insides from TRIUMF, Canada’s Only Proton Beam Therapy Center
A large analysis from the National Cancer Database found that after matching patients for comparable characteristics, five-year overall survival with brachytherapy (plaque radiation) versus enucleation was 87% versus 64% for small tumors, 77% versus 57% for medium, and 68% versus 46% for large tumors. Brachytherapy carried a significant survival advantage in that analysis, though it’s worth noting that the patients who undergo enucleation tend to have more advanced disease to begin with, and even with statistical matching, residual differences likely persist.16PubMed Central. Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database The same analysis identified ciliary body invasion, extension beyond the eye, older age, and larger tumor size as negative prognostic factors regardless of treatment type.
Eye-preserving radiation is not without trade-offs. Proton beam therapy can maintain useful vision, but it also carries risks including neovascular glaucoma, radiation damage to the retina, retinal detachment, and local tumor recurrence. These complications can erode quality of life even when the cancer itself is controlled.
Systemic Treatment for Metastatic Disease
Historically, there were no systemic therapies proven to extend life in metastatic uveal melanoma. Standard chemotherapy and even the immune checkpoint inhibitors that revolutionized skin melanoma treatment showed poor results here. That changed with tebentafusp, a bispecific protein that redirects immune cells to attack tumor cells carrying a specific surface marker. In a pivotal trial, one-year overall survival was 73% with tebentafusp compared to 59% with the best available alternatives.17PubMed. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Three-year follow-up data confirmed the benefit, with median overall survival of about 22 months for tebentafusp versus 17 months for the control arm, and an estimated 27% of tebentafusp-treated patients alive at three years compared to 18% on control therapy.18PubMed Central. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma While those numbers are a genuine advance, they also underscore how difficult this disease remains: most patients with metastatic uveal melanoma still do not survive long-term even with the best current systemic therapy. Tebentafusp also requires patients to carry a specific immune system marker (HLA-A*02:01), which limits eligibility to roughly half of patients with European ancestry.
Liver-Directed Treatments
Because metastatic disease is so heavily concentrated in the liver, treatments that target the liver directly have become an important part of the toolkit. Several approaches are in use, including selective internal radiotherapy (SIRT, where tiny radioactive beads are delivered into the liver’s blood supply), chemosaturation with percutaneous hepatic perfusion (PHP, where high-dose melphalan is infused directly through the liver and then filtered from the blood before it circulates elsewhere), and transarterial chemoembolization (TACE).
A retrospective multicenter study comparing these approaches found that SIRT and PHP had similar median overall survival, roughly 25 months each, while TACE was associated with significantly shorter survival at about 11 months.19The Oncologist. Selective internal radiotherapy and chemosaturation show equivalent survival in metastatic uveal melanoma: a retrospective multicenter study In a dedicated PHP study, median overall survival from first treatment was about 15 months, with one-year and two-year survival of 62% and 27%, respectively.20PubMed Central. Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma Case reports have also documented responses to liver-directed treatment in patients who progressed through prior systemic therapy, suggesting that sequencing systemic and liver-directed approaches can extend disease control.21PubMed Central. Successful application of chemosaturation with percutaneous hepatic perfusion in metastatic uveal melanoma patient progressing after systemic treatment options: a case report
Surveillance After Treatment
Because metastases can appear many years after the primary tumor is treated, ongoing monitoring is critical. A ten-year retrospective analysis at a major UK ocular oncology center found that 37% of uveal melanoma patients developed metastases during the study period, with 87% of those detected within five years of primary treatment and 97% within ten years.22PubMed Central. A Retrospective Analysis of 10 Years of Liver Surveillance Undertaken in Uveal Melanoma Patients Treated at the Supraregional “Liverpool Ocular Oncology Centre”, UK
The intensity of surveillance matters. A study comparing standard and enhanced surveillance protocols found that more frequent imaging detected smaller liver metastases, with average lesion size around 1.5 to 1.6 cm under enhanced protocols versus 6.1 cm under standard protocols. Patients on enhanced monitoring had a substantially lower rate of developing large (greater than 3 cm) metastases at two years.23PubMed Central. Surveillance for Metastasis in High-Risk Uveal Melanoma Patients: Standard versus Enhanced Protocols Catching metastases when they’re small potentially opens the door to more effective liver-directed treatments, since several of those approaches work best on limited disease. Most ocular oncologists tailor surveillance intensity to the tumor’s molecular risk class, with high-risk patients getting more frequent liver imaging, often every three to six months for the first five years.
Ocular Melanoma in Children and Young Adults
Uveal melanoma in people under 20 is exceedingly rare, and the genetics can look different from the adult form. A European survey of pediatric and young adult cases found a mean metastasis-free survival of about 9 years, though median survival was shorter at 5.5 years because a few patients survived very long. Germline BAP1 mutations, which raise concern for a hereditary cancer predisposition syndrome, were found in about 4% of tested cases. As in adults, tumors with somatic BAP1 loss had shorter metastasis-free survival.24PubMed Central. The Pediatric and Young Adult Choroidal and Ciliary Body Melanoma Genetic Study, A Survey by the European Ophthalmic Oncology Group Notably, males survived longer than females in that cohort, a finding that differs from some adult series and remains unexplained.
Quality of Life Beyond Survival
Prognosis isn’t only about years of life. A systematic review of quality-of-life studies in eye cancer patients found conflicting results: about half of the included studies reported that patients’ overall quality of life was similar to or better than the general population, while the other half found it was worse. Treatment type, sex, and age all influenced outcomes. Radiation therapy can preserve the eye but introduces complications that affect daily function, and the psychological burden of living under surveillance for metastasis weighs on many patients even when their objective prognosis is good.
Emerging Tools for Monitoring and Prediction
Two developing technologies are worth watching. Liquid biopsy, which looks for tumor-derived material in a simple blood draw, could eventually allow doctors to detect micrometastatic disease or monitor treatment response without repeated imaging. In uveal melanoma, where diagnosis traditionally relies on imaging and repeat biopsies are impractical, a reliable blood-based biomarker would fill a real gap. The technology is not yet standard practice, but active research is underway.25PubMed Central. Liquid Biopsy in Uveal Melanoma: Are We There Yet?
Artificial intelligence is also entering the field. Researchers have trained deep-learning models to predict gene expression profile class directly from digital images of biopsy slides, achieving accuracy above 90% in pilot studies.26PubMed Central. Artificial intelligence for ocular oncology If validated in larger studies, this could make molecular prognostication faster and more accessible, particularly in centers without specialized genomic testing. Neither liquid biopsy nor AI-based image analysis has replaced current standard-of-care testing, but both are moving quickly enough that patients diagnosed in the next several years may benefit from one or both.